Edwards Reconciled Depreciation vs Extraordinary Items Analysis
EW Stock | USD 89.14 0.97 1.08% |
Edwards Lifesciences financial indicator trend analysis is much more than just examining Edwards Lifesciences Corp latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Edwards Lifesciences Corp is a good investment. Please check the relationship between Edwards Lifesciences Reconciled Depreciation and its Extraordinary Items accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Edwards Lifesciences Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in housing.
Reconciled Depreciation vs Extraordinary Items
Reconciled Depreciation vs Extraordinary Items Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Edwards Lifesciences Corp Reconciled Depreciation account and Extraordinary Items. At this time, the significance of the direction appears to have strong relationship.
The correlation between Edwards Lifesciences' Reconciled Depreciation and Extraordinary Items is 0.73. Overlapping area represents the amount of variation of Reconciled Depreciation that can explain the historical movement of Extraordinary Items in the same time period over historical financial statements of Edwards Lifesciences Corp, assuming nothing else is changed. The correlation between historical values of Edwards Lifesciences' Reconciled Depreciation and Extraordinary Items is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Reconciled Depreciation of Edwards Lifesciences Corp are associated (or correlated) with its Extraordinary Items. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Extraordinary Items has no effect on the direction of Reconciled Depreciation i.e., Edwards Lifesciences' Reconciled Depreciation and Extraordinary Items go up and down completely randomly.
Correlation Coefficient | 0.73 |
Relationship Direction | Positive |
Relationship Strength | Significant |
Reconciled Depreciation
Extraordinary Items
Most indicators from Edwards Lifesciences' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Edwards Lifesciences Corp current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Edwards Lifesciences Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in housing. At this time, Edwards Lifesciences' Selling General Administrative is fairly stable compared to the past year. Sales General And Administrative To Revenue is likely to climb to 0.36 in 2024, whereas Issuance Of Capital Stock is likely to drop slightly above 169.1 M in 2024.
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 4.0B | 4.3B | 4.6B | 4.9B | Total Revenue | 5.2B | 5.4B | 6.0B | 6.3B |
Edwards Lifesciences fundamental ratios Correlations
Click cells to compare fundamentals
Edwards Lifesciences Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Edwards Lifesciences fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 6.5B | 7.2B | 8.5B | 8.3B | 9.4B | 9.8B | |
Other Current Liab | 6.4M | 39.3M | 3.9M | 311M | 15.2M | 14.4M | |
Total Current Liabilities | 902.4M | 893.9M | 1.0B | 1.0B | 1.2B | 1.3B | |
Total Stockholder Equity | 4.1B | 4.6B | 5.8B | 5.8B | 6.7B | 7.0B | |
Property Plant And Equipment Net | 1.1B | 1.5B | 1.6B | 1.7B | 1.8B | 1.9B | |
Retained Earnings | 3.7B | 4.6B | 6.1B | 7.6B | 9.0B | 9.4B | |
Non Current Assets Total | 3.5B | 4.1B | 5.3B | 5.2B | 5.3B | 5.6B | |
Non Currrent Assets Other | 101.8M | 119.6M | 110.8M | 299.1M | 463.7M | 486.9M | |
Cash And Short Term Investments | 1.5B | 1.4B | 1.5B | 1.2B | 1.6B | 1.7B | |
Net Receivables | 599.1M | 602.8M | 664.9M | 699.1M | 836.9M | 878.7M | |
Good Will | 1.2B | 1.2B | 1.2B | 1.2B | 1.3B | 688.6M | |
Common Stock Shares Outstanding | 636.6M | 631.9M | 631.2M | 624.2M | 609.4M | 550.8M | |
Liabilities And Stockholders Equity | 6.5B | 7.2B | 8.5B | 8.3B | 9.4B | 9.8B | |
Non Current Liabilities Total | 1.4B | 1.8B | 1.6B | 1.5B | 1.4B | 800.7M | |
Inventory | 640.9M | 802.3M | 726.7M | 875.5M | 1.2B | 1.2B | |
Other Current Assets | 168M | 208.2M | 237.1M | 195.9M | 239.3M | 251.3M | |
Other Stockholder Equity | 344.6M | (466M) | (716.5M) | (2.2B) | (2.8B) | (2.6B) | |
Total Liab | 2.3B | 2.7B | 2.7B | 2.5B | 2.6B | 1.4B | |
Property Plant And Equipment Gross | 1.1B | 1.5B | 1.6B | 1.7B | 2.7B | 2.8B | |
Total Current Assets | 3.0B | 3.1B | 3.2B | 3.1B | 4.0B | 4.2B | |
Accumulated Other Comprehensive Income | (156M) | (161.1M) | (157.7M) | (254.9M) | (242.8M) | (230.7M) | |
Short Long Term Debt Total | 593.8M | 678.8M | 694.9M | 690.3M | 691.3M | 486.4M | |
Other Liab | 784.1M | 1.1B | 969.6M | 797.6M | 917.2M | 963.1M | |
Net Debt | (500.3M) | (488.3M) | (172.5M) | (77.7M) | (449.1M) | (426.6M) | |
Accounts Payable | 180.4M | 196.5M | 204.5M | 201.9M | 201.4M | 139.5M | |
Cash | 1.2B | 1.2B | 862.8M | 769M | 1.1B | 1.2B | |
Other Assets | 274M | 1.2B | 357.5M | 783.1M | 900.6M | 945.6M | |
Long Term Debt | 594.4M | 595M | 595.7M | 596.3M | 597M | 425.6M | |
Common Stock Total Equity | 218.1M | 636.4M | 642M | 646.3M | 743.2M | 780.4M | |
Short Term Debt | 598M | 0.0 | 25.5M | 27.2M | 24.9M | 23.7M | |
Intangible Assets | 336.5M | 331.4M | 323.6M | 285.2M | 428.4M | 449.8M | |
Common Stock | 218.1M | 636.4M | 642M | 646.3M | 650.5M | 683.0M | |
Property Plant Equipment | 1.1B | 1.4B | 1.6B | 1.7B | 2.0B | 2.1B | |
Treasury Stock | (1.0B) | (1.3B) | (1.9B) | (2.4B) | (2.2B) | (2.1B) | |
Short Term Investments | 337.8M | 219.4M | 604M | 446.3M | 500.5M | 382.6M | |
Net Tangible Assets | 2.9B | 3.4B | 4.3B | 4.4B | 5.0B | 5.3B | |
Retained Earnings Total Equity | 3.7B | 4.6B | 6.1B | 7.6B | 8.7B | 9.2B | |
Capital Surpluse | 1.6B | 1.4B | 1.7B | 2.0B | 2.3B | 1.2B | |
Long Term Investments | 585.5M | 801.6M | 1.8B | 1.2B | 583.9M | 582.2M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Edwards Lifesciences Corp is a strong investment it is important to analyze Edwards Lifesciences' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Edwards Lifesciences' future performance. For an informed investment choice regarding Edwards Stock, refer to the following important reports:Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Edwards Lifesciences Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in housing. You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Complementary Tools for Edwards Stock analysis
When running Edwards Lifesciences' price analysis, check to measure Edwards Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Edwards Lifesciences is operating at the current time. Most of Edwards Lifesciences' value examination focuses on studying past and present price action to predict the probability of Edwards Lifesciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Edwards Lifesciences' price. Additionally, you may evaluate how the addition of Edwards Lifesciences to your portfolios can decrease your overall portfolio volatility.
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |
Is Edwards Lifesciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Edwards Lifesciences. If investors know Edwards will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Edwards Lifesciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.036 | Earnings Share 2.32 | Revenue Per Share 10.151 | Quarterly Revenue Growth 0.095 | Return On Assets 0.1205 |
The market value of Edwards Lifesciences Corp is measured differently than its book value, which is the value of Edwards that is recorded on the company's balance sheet. Investors also form their own opinion of Edwards Lifesciences' value that differs from its market value or its book value, called intrinsic value, which is Edwards Lifesciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Edwards Lifesciences' market value can be influenced by many factors that don't directly affect Edwards Lifesciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Edwards Lifesciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Edwards Lifesciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Edwards Lifesciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.